• Press Office

    Posted in category ABPI statement by Press Office on 03/01/2014

    ABPI response to the Public Accounts Committee report: 'Access to clinical trial information and the stockpiling of Tamiflu'

Commenting on the publication of the Public Accounts Committee report: 'Access to clinical trial information and the stockpiling of Tamiflu' Bina Rawal, Research, Medical and Innovation Director at the ABPI said: “The ABPI is a strong advocate for transparency in clinical trial data and the role it plays in improving patient care."

 

​Bina Rawal continued:

"It is misleading to suggest that the pharmaceutical industry routinely withholds clinical trial data from doctors and researchers.

“In late 2013, an ABPI commissioned study was published in a peer reviewed journal. This study highlighted a positive trend of increasing levels of disclosure for industry-sponsored clinical trials, with almost nine out of ten of all industry-sponsored clinical trials disclosed by 31 January 2013¹. The research covers new medicines approved between 2009 - 2011, which includes trials conducted over the preceding 10 or more years – i.e. during the entire development program.

“However we recognise that there is still work to be done and we are continuing on a journey to achieving greater clinical trial transparency. The ABPI has made available a new clinical trial disclosure toolkit to assist companies and will continue to engage with key stakeholders on this issue.”

Notes to editor

¹The research shows that over three quarters (76%) of all industry-sponsored clinical trials for new medicines recently approved by the European Medicines Agency (EMA) had some results disclosed within a year of completion or of regulatory approval. Rates of disclosure have continued to rise and almost nine in ten (89%) of these trials had disclosed results by 31 January 2013.

About the ABPI

The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.

Media enquiries

ABPI Press Office

Tel: +44 (0) 20 7747 1441

Mobile: +44 (0) 7850 312064

Email: pressoffice@abpi.org.uk

 

 

 

 
Print this page icon Print this page
 
Please choose the subject of your enquiry from the list below:
 
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.